Molecular and cellular mechanisms of DNA vaccines
- PMID: 18535407
- DOI: 10.4161/hv.4.6.6200
Molecular and cellular mechanisms of DNA vaccines
Abstract
Although DNA vaccines are already in use for treatment of some animal diseases, they suffer from lower immunogenicity in humans which limits their effectiveness. Thus, recent studies have been focused on strategies to improve the immunogenicity of DNA vaccines. However, there is little known about the molecular and immunological mechanisms by which DNA vaccines work. It has long been the central dogma that DNA vaccine immunogenicity can be attributed to its immunostimulatory CpG motifs acting as 'a built-in adjuvant", which is recognized by Toll-like receptor (TLR) 9, the sole receptor for CpG motifs. Recent research, however, has provided evidence for a new mechanism of action for DNA vaccines. It was reported that the adjuvant effect of plasmid DNA is mediated by its double-stranded structure, which activates TBK1-dependent innate immune signaling pathways in the absence of TLRs. Moreover, TBK1-signaling may delineate direct or indirect (cross) antigen presentation through distinct types of cells in vivo, critical for the induction of antigen-specific CD4(+) or CD8(+) T cells, respectively. This additional information about the mechanism of action of DNA vaccines will lead to improvements in their efficacy and safety.
Similar articles
-
TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines.Nature. 2008 Feb 7;451(7179):725-9. doi: 10.1038/nature06537. Nature. 2008. PMID: 18256672
-
Novel strategies to improve DNA vaccine immunogenicity.Curr Gene Ther. 2011 Dec;11(6):479-84. doi: 10.2174/156652311798192815. Curr Gene Ther. 2011. PMID: 22023477 Review.
-
B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines.Oncotarget. 2016 Oct 18;7(42):67901-67918. doi: 10.18632/oncotarget.12178. Oncotarget. 2016. PMID: 27661128 Free PMC article.
-
Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model.Cancer Immunol Immunother. 2018 Apr;67(4):627-638. doi: 10.1007/s00262-017-2111-y. Epub 2018 Jan 12. Cancer Immunol Immunother. 2018. PMID: 29330557 Free PMC article.
-
[DNA vaccine].Nihon Rinsho. 2008 Oct;66(10):1867-72. Nihon Rinsho. 2008. PMID: 18939483 Review. Japanese.
Cited by
-
Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions.Vaccines (Basel). 2023 Apr 29;11(5):919. doi: 10.3390/vaccines11050919. Vaccines (Basel). 2023. PMID: 37243023 Free PMC article. Review.
-
Toward Establishing an Ideal Adjuvant for Non-Inflammatory Immune Enhancement.Cells. 2022 Dec 11;11(24):4006. doi: 10.3390/cells11244006. Cells. 2022. PMID: 36552770 Free PMC article. Review.
-
Nanoparticle-Based Delivery Systems for Vaccines.Vaccines (Basel). 2022 Nov 17;10(11):1946. doi: 10.3390/vaccines10111946. Vaccines (Basel). 2022. PMID: 36423041 Free PMC article. Review.
-
Phase I Study to Assess the Safety and Immunogenicity of an Intradermal COVID-19 DNA Vaccine Administered Using a Pyro-Drive Jet Injector in Healthy Adults.Vaccines (Basel). 2022 Aug 30;10(9):1427. doi: 10.3390/vaccines10091427. Vaccines (Basel). 2022. PMID: 36146505 Free PMC article.
-
Plasmid DNA for Therapeutic Applications in Cancer.Pharmaceutics. 2022 Sep 3;14(9):1861. doi: 10.3390/pharmaceutics14091861. Pharmaceutics. 2022. PMID: 36145609 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous